Clare Stuart, general manager, TSA. In addition to early surveillance and surgery, there are two other areas of research that have the potential to deliver new treatment options for people with epilepsy caused by tuberous sclerosis: mTOR inhibitor medicine and … Read More
From an interview with Dr Simon Harvey, paediatric neurologist and director of the Children’s Epilepsy Program at Royal Children’s Hospital, Melbourne. This article was first published in the October 2016 issue of Reach Out, TSA’s twice-yearly magazine. What is epilepsy … Read More
From an interview with Dr Kate Riney, paediatric neurologist and TSC clinic lead at Lady Cilento Children’s Hospital, Brisbane. This article was first published in the October 2016 issue of Reach Out, TSA’s twice-yearly magazine. Can you describe this new … Read More
We’ve updated our information on the availability of this new treatment for facial angiofibromas.
The American Thoracic Society (ATS) and the Japanese Respiratory Society (JRS) have published new clinical practice guidelines for the diagnosis and management of lymphangioleiomyomatosis (LAM), a rare lung disease that primarily affects women of child-bearing age and is associated with … Read More
Topical Rapamycin is an experimental treatment for facial angiofibromas, which affect the majority of people with Tuberous Sclerosis. A formal clinical trial, funded by generous donors to Tuberous Sclerosis Australia, has completed at Sydney Children’s Hospital which aims to provide … Read More
Tuberous Sclerosis Australia, with thanks to the TSC Heroes, are proud to support this research project. Our partner in this project is the Australian Mitochondrial Disease Foundation and the research is being conducted by the Australian Paediatric Surveillance Unit, part … Read More
A report from the 2015 International TSC Research Conference in Windsor, United Kingdom September 10-12th. From Treatment to Prevention, the global TSC research community asks if postponing the complications of TSC indefinitely is the path to a cure for TSC.
Tuberous Sclerosis Australia has published two new resources to help individuals with TSC and their families understand new medicines for TSC. Names of mTOR inhibitor medicines include Afinitor, Everolimus, Sirolimus, Rapamune, and Rapamycin. Read our updated information page on mTOR … Read More
Tuberous Sclerosis Australia (TSA) was represented at the recent international TSC research conference in Windsor, UK. This included presentation of results of the TSC family survey conducted by TSA in 2014. Thanks again to all the families who responded. Download … Read More